Hexamethylbisacetamide and Disruption of Human Immunodeficiency Virus Type 1 Latency in CD4+T Cells

Abstract excerpt

BACKGROUND: Novel therapeutic approaches are needed to attack persistent proviral human immunodeficiency type 1 (HIV-1) infection. Hexamethylbisacetamide (HMBA), a hybrid bipolar compound, induces expression of the HIV-1 promoter in the long terminal repeat (LTR) region in a Tat-independent manner but mimics the effect of Tat, overcoming barriers to LTR expression and increasing the processivity of LTR...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV Research and Treatment
• Share to Immune Cell Function and Interaction